Method for separating homoduplexed and heteroduplexed nucleic acids

Patent metadata

Field	Value
Publication number	US-9340835-B2
Application number	US-201414210696-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	May 17, 2016
Grant date	May 17, 2016

Abstract

The invention includes methods and apparatus for separating heteroduplexed nucleic acids from homoduplexed nucleic acids having similar sequences and being at a much higher concentration. The heteroduplexed nucleic acids may be separated through the application of a time varying driving field and a time-varying mobility field to a sample of heteroduplexed and homoduplexed nucleic acids in a separation medium. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.

First claim

What is claimed is:

1. A method for separating a mixture of homoduplexed and heteroduplexed nucleic acids, comprising;
loading a sample comprising a mixture of homoduplexed and heteroduplexed nucleic acids on a separation medium;
applying a time-varying driving field to the separation medium; and
applying a time-varying mobility varying field to the separation medium,
thereby causing the homoduplexed nucleic acids to be separated from the heteroduplexed nucleic acids.

2. The method of claim 1 , wherein the time-varying mobility varying field is temperature.

3. The method of claim 1 , wherein the time-varying driving field comprises two non-collinear electric fields.

4. The method of claim 1 , wherein the time-varying driving field comprises three non-collinear electric fields.

5. The method of claim 1 , wherein the heteroduplexed nucleic acids comprise a first sequence and a second sequence, and either the first or the second sequence is known.

6. The method of claim 5 , wherein the known sequence comprises a sequence that is associated with an oncogene.

7. The method of claim 6 , wherein the oncogene is selected from a RAS-related oncogene, a p53-related tumor suppressor gene, and a WNT-related oncogene.

8. The method of claim 1 , wherein the heteroduplexed nucleic acids comprise a first sequence and a second sequence, and neither the first nor the second sequence is known.

9. The method of claim 1 , wherein the heteroduplexed nucleic acids comprise a first sequence and a second sequence and the first and second sequences are complementary strand paired except for a mutation selected from a nucleotide polymorphism, a base deletion, or a base insertion.

10. The method of claim 9 , wherein the mutation is a single nucleotide polymorphism (SNP).

11. The method of claim 1 , wherein the heteroduplexed nucleic acids comprise a first sequence and a second sequence and the first and second sequences are complementary strand paired except for a chemical modification selected from differential methylation or differential acetylation.

12. The method of claim 1 , further comprising:
obtaining a sample comprising nucleic acids;
denaturing the nucleic acids to produce single-stranded oligomers; and
reannealing the single-stranded oligomers to create a sample comprising a mixture of homoduplexed and heteroduplexed nucleic acids.

13. The method of claim 12 , wherein the sample comprising nucleic acids comprises a dominant nucleic acid sequence comprising a majority of the nucleic acid sequences in the sample.

14. The method of claim 13 , wherein at least a portion of the heteroduplexed nucleic acids comprises a pairing strand having the dominant nucleic acid sequence and a non-dominant nucleic acid sequence.

15. The method of claim 1 , further comprising recovering the heteroduplexed nucleic acids.

16. The method of claim 15 , further comprising amplifying the recovered heteroduplexed nucleic acids.

17. The method of claim 15 , further comprising sequencing the recovered heteroduplexed nucleic acids.

18. The method of claim 12 , wherein the sample comprising nucleic acids comprises PCR amplicons.

19. The method of claim 18 , wherein the PCR amplicons comprise primers with a GC clamp region.

20. A method for determining a mutation in a nucleic acid sample, comprising:
amplifying a plurality of non-identical nucleic acids in a sample to create a plurality of non-identical amplicons;
denaturing and reannealing the non-identical amplicons to produce a sample comprising a mixture of homoduplexed and heteroduplexed nucleic acids;
loading the sample comprising a mixture of homoduplexed and heteroduplexed nucleic acids on a separation medium;
applying both a time-varying driving field and a time-varying mobility varying field to the separation medium, thereby causing the homoduplexed nucleic acids to be separated from the heteroduplexed nucleic acids; and
recovering the heteroduplexed nucleic acids.

Assignees

• Boreal Genomics Corp
• Univ British Columbia

Inventors

• Marziali Andrea
• Pel Joel

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2565/131

  Single/double strand conformational analysis, i.e. SSCP/DSCP · CPC title

• C12Q2537/107

  Homoduplex formation · CPC title